达格列净联合二甲双胍、阿卡波糖治疗血糖控制效果不佳2型糖尿病患者的效果观察

Observation on the Effect of Dapagliflozin Combined with Metformin and Acarbose in the Treatment of Type 2 Diabetes Mellitus Patients with Poor Blood Glucose Control

目的观察达格列净联合二甲双胍、阿卡波糖治疗血糖控制效果不佳2型糖尿病患者的临床效果。方法将99例血糖控制效果不佳2型糖尿病患者根据治疗方法不同分为观察组(n=50)和对照组(n=49)。对照组仅采用二甲双胍、阿卡波糖治疗,观察组在对照组基础上采用达格列净治疗。比较两组患者的血糖[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]水平、血脂[总胆固醇(TC)、甘油三酯(TG)]水平及不良反应。结果治疗后,两组的FPG、2hPG、HbA1c水平均降低,且观察组的FPG、2hPG、HbA1c水平低于对照组(P<0.05)。治疗后,两组的血清TC、TG水平均降低,且观察组的TC、TG水平低于对照组(P<0.05)。两组的不良反应发生率(2.00%vs.0.00%)比较差异无统计学意义(P>0.05)。结论达格列净联合二甲双胍、阿卡波糖治疗血糖控制效果不佳2型糖尿病患者的效果显著,可有效改善患者的血糖、血脂水平,且安全性较高,值得临床推广应用。

Objective To observe the clinical effect of dapagliflozin combined with metformin and acarbose in the treatment of type 2 diabetes mellitus patients with poor blood glucose control.Methods 99 type 2 diabetes mellitus patients with poor blood glucose control were divided into observation group(n=50)and control group(n=49)according to different treatment methods.The control group was only treated with metformin and acarbose,and the observation group was treated with dapagliflozin on the basis of the control group.The blood glucose(FPG,2hPG,HbA1c)levels,blood lipid(TC,TG)levels and adverse reactions were compared between the two groups.Results After treatment,the FPG,2hPG and HbA1c levels of the two groups decreased,and the FPG,2hPG and HbA1c levels of the observation group were lower than those of the control group(P<0.05).After treatment,the serum TC and TG levels of the two groups decreased,and the TC and TG levels of the observation group were lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions(2.00%vs.0.00%)between the two groups(P>0.05).Conclusions Dapagliflozin combined with metformin and acarbose has significant effect in the treatment of type 2 diabetes mellitus patients with poor blood glucose control,and can effectively improve their blood glucose and blood lipid levels with higher safety,which is worthy of clinical promotion and application.